Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial

11 Jul 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Syndromes and Imprinting
Share to Prenatal Screening and Diagnostics
Share to RNA modifications and cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40646322
DOI: 10.1038/s41591-025-03784-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trialPMID 40646322Read ↗

Therapies in preclinical and clinical development for Angelman syndromeSemantic proximity Read ↗

Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman SyndromeSemantic proximity Read ↗

Emerging Therapies and challenges for individuals with Angelman syndrome.Semantic proximity Read ↗

Ube3a unsilencer for the potential treatment of Angelman syndromeSemantic proximity Read ↗

Development of an ASO therapy for Angelman syndrome by targeting an evolutionarily conserved region at the start of the <i>UBE3A-AS</i> transcriptSemantic proximity Read ↗

An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript.Semantic proximity Read ↗

Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.Semantic proximity Read ↗

[Angelman syndrome--diagnosis and therapy of genomic imprinting disorders].Semantic proximity Read ↗

FDA-Approved Oligonucleotide Therapies in 2017Semantic proximity Read ↗

Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatmentsSemantic proximity Read ↗

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disordersSemantic proximity Read ↗

Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.